Individual suit filings related to the antipsychotic drug Risperdal have been increasing in the Philadelphia Court of Common Pleas, First Judicial District leaders say.

The uptick has been steady since actions against Johnson & Johnson and its subsidiaries began four years ago, according to the court officials.